Document is current
Any future updates will be listed below
-
Authors
Uemura, Hirotsugu https://orcid.org/0000-0002-3665-9523
Tomita, Yoshihiko
Nonomura, Norio
Yoshizaki, Kenji
Nakao, Takafumi
Shinohara, Nobuo
-
Funding
Funding for this research was provided by:
Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.
- License Information
-
More Information
Article History
Received: 23 November 2021
Accepted: 6 March 2022
First Online: 20 April 2022
Declarations
:
: Hirotsugu Uemura has served in an advisory role for Ono Pharmaceutical Co., Ltd., Sanofi, and Janssen Pharmaceuticals; received honoraria (e.g., lecture fees) from Bristol Myers Squibb K. K., Bayer, Pfizer Inc., Sanofi, and Janssen Pharmaceuticals; and received research funding from AstraZeneca, The Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Janssen Pharmaceuticals, Sanofi, Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical, and Daiichi Sankyo Company. Yoshihiko Tomita received honoraria (e.g., lecture fees) from Astellas Pharma Inc., Bristol Myers Squibb K. K., Novartis, Pfizer Inc., Taiho Pharmaceutical Co., Ltd., The Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Terumo Corporation, MSD, and Merck & Co., Inc. and research funding from Astellas Pharma Inc., AstraZeneca, Ono Pharmaceutical Co., Ltd., The Chugai Pharmaceutical Co., Ltd., and The Takeda Pharmaceutical Company Limited. Norio Nonomura received honoraria (e.g., lecture fees) from The Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., AstraZeneca, and Merck & Co., Inc. and research funding from The Takeda Pharmaceutical Company Limited, Nippon Shinyaku Co. Ltd., and Taiho Pharmaceutical Co., Ltd. Kenji Yoshizaki and Takafumi Nakao are employees of Ono Pharmaceutical Co., Ltd. Nobuo Shinohara received honoraria (e.g., lecture fees) from Pfizer Inc., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb K. K., Novartis, Astellas Pharma Inc., The Takeda Pharmaceutical Company Limited, and MSD; fees for promotional materials (e.g., manuscript fees) from Ono Pharmaceutical Co., Ltd. and Bristol Myers Squibb K. K.; and research funding from Ono Pharmaceutical Co., Ltd., The Takeda Pharmaceutical Company Limited, and Astellas Pharma Inc.
